Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Bole Tian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2577-5131; OpenAlex author ID A5101541180. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper · 2026: 4 papers

Papers 21

  1. LINC00852 Enhances Glycolysis and Tumor Immunity in Pancreatic Cancer via the miR‑494‑3p/GPX8 Axis. Last author DOI 10.1002/jbt.70871↗
  2. A Naples prognostic score-based nomogram enhances perioperative risk stratification for resected pancreatic cancer. First author DOI 10.1080/14796694.2026.2687698↗
  3. Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II … Co-author DOI 10.1158/1078-0432.ccr-26-1824↗
  4. Analysis of the Safety and Efficacy of Cryoablation in Patients with Locally Advanced Pancreatic Cancer. Last author DOI 10.1245/s10434-026-20731-z↗
  5. A retrospective cohort study on the differential overall survival rates between surgical intervention and chemotherapy in stage IV pancreatic cancer patients. Last author DOI 10.21037/gs-2025-269↗
  6. Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal a… Co-author DOI 10.1038/s41392-024-02031-8↗
  7. Perioperative outcomes and long-term survival of cryosurgery on unresectable pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.1097/js9.0000000000001407↗
  8. A commentary on 'Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer'. Last author DOI 10.1097/js9.0000000000001568↗
  9. Simultaneous resection of oligometastatic pancreatic cancer: The 5-Year follow-up in a single center. Last author DOI 10.1016/j.asjsur.2022.07.027↗
  10. Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single cen… Last author DOI 10.3389/fonc.2022.966256↗
  11. Prognostic role of the prognostic nutritional index in patients with pancreatic cancer who underwent curative resection without preoperative neoadjuvant treatm… Last author DOI 10.3389/fsurg.2022.992641↗
  12. Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison to pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.suronc.2021.101528↗
  13. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-021-02972-6↗
  14. Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma. Last author DOI 10.1097/md.0000000000019504↗
  15. Five gene signatures were identified in the prediction of overall survival in resectable pancreatic cancer. Last author DOI 10.1186/s12893-020-00856-y↗
  16. The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanced Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-60530/v1↗
  17. An Unexpected Case Report of Adrenal Lymphangioma: Mimicking Metastatic Tumor on Imaging in a Patient With Pancreatic Cancer. Co-author DOI 10.3389/fendo.2020.610744↗
  18. Assessment of preoperative hypercoagulability in patients with pancreatic ductal adenocarcinoma (PDAC) using rapid thromboelastography (r-TEG). Last author DOI 10.1007/s11239-019-01908-8↗
  19. Positron emission tomography modalities prevent futile radical resection of pancreatic cancer: A meta-analysis. Last author DOI 10.1016/j.ijsu.2017.09.003↗
  20. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  21. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changyuan Wang · 2 shared papers, 2024–2026 · strength 0.86
  2. Zuowei Wu · 4 shared papers, 2020–2023 · strength 0.85
  3. Li Mao · 6 shared papers, 2019–2022 · strength 0.79
  4. Shutong Shao · 2 shared papers, 2025–2026 · strength 0.67
  5. Kang Xue · 2 shared papers, 2024–2026 · strength 0.56
  6. Junjie Xiong · 3 shared papers, 2021–2026 · strength 0.50
  7. Jun Yang · 1 shared paper, 2026 · strength 0.50
  8. Chao Wu · 1 shared paper, 2026 · strength 0.50
  9. Yi Cheng · 3 shared papers, 2021–2026 · strength 0.46
  10. Hao Chen · 1 shared paper, 2025 · strength 0.37
  11. Yi Li · 1 shared paper, 2024 · strength 0.36
  12. Chao Wu · 2 shared papers, 2020–2022 · strength 0.35
  13. Xing Huang · 2 shared papers, 2022 · strength 0.35
  14. Zihe Wang · 2 shared papers, 2022 · strength 0.35
  15. Li Wang · 1 shared paper, 2026 · strength 0.30
  16. Dan Cao · 1 shared paper, 2026 · strength 0.30
  17. Li Wang · 2 shared papers, 2020–2022 · strength 0.29
  18. Dan Cao · 2 shared papers, 2020–2021 · strength 0.24
  19. Ang Li · 2 shared papers, 2020–2021 · strength 0.22
  20. Lin Shui · 2 shared papers, 2020–2021 · strength 0.22
  21. Zixing Huang · 1 shared paper, 2026 · strength 0.19
  22. Chen Chang · 1 shared paper, 2026 · strength 0.19
  23. Ke Cheng · 1 shared paper, 2026 · strength 0.19
  24. Dan Cao · 1 shared paper, 2026 · strength 0.19
  25. Xiaorui Zhu · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.